Diagnostic role of galectin-3 in follicular thyroid tumors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

1. Galectin-3 marker expression in renal cell carcinoma and correlation with patient's clinicopathologic factors: A cross-sectional study.Caspian journal of internal medicine · 2025
   Article
2. Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.BMB reports · 2020
   Review
3. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.OncoTargets and therapy · 2016
   Article
4. Extracellular galectin-3 in tumor progression and metastasis.Frontiers in oncology · 2014
   Review
5. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.Endocrine pathology · 2010
   Article
6. The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.Cancers · 2010
   Article
7. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors.Endocrine · 2009
   Article
8. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.Journal of Korean medical science · 2007
   Article
9. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.Annals of surgery · 2005
   Article
10. Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.Virchows Archiv : an international journal of pathology · 2005
    Article
11. Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.Journal of endocrinological investigation · 2005
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as